Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer

This review of 15 trials (n=5893) suggests that single‐agent immune checkpoint inhibitors in people with NSCLC and PD‐L1 ≥50% probably leads to a higher overall survival rate and may lead to a higher progression‐free survival and response rate vs platinum‐based chemotherapy.

Source:

Cochrane Database of Systematic Reviews